Return to homepagePandemic Pact

Treating severe COVID-19 associated secondary bacterial infections with Phage Therapy under the Declaration of Helsinki / Consortium: COVID-19_Phage

Grant number: unknown

Grant search

Key facts

  • Disease

    COVID-19

  • Start & end year

    2020
    2022

  • Known Financial Commitments (USD)

    $462,484.48

  • Funder

    Academy of Finland

  • Principal Investigator

    Matti Jalasvuori

  • Research Location

    Finland

  • Lead Research Institution

    University of Jyväskylä

  • Research Priority Alignment

    N/A

  • Research Category

    Clinical characterisation and management

  • Research Subcategory

    Supportive care, processes of care and management

  • Special Interest Tags

    N/A

  • Study Type

    Non-Clinical

  • Clinical Trial Details

    N/A

  • Broad Policy Alignment

    Pending

  • Age Group

    Not Applicable

  • Vulnerable Population

    Not applicable

  • Occupations of Interest

    Not applicable

Abstract

Bacteriophages are viruses that infect and kill bacterial cells. SARS-Cov-2 infektion weakens the innate immune defense of lungs, which makes the patient susceptible to sometimes lethal bacterial pneumonia. Hospital acquired bacterial infections are often caused by pathogens that are resistant to antibiotics, which leaves very few treatment options. In the proposed project, we will isolate and prepare bacteriophages against the most problematic antibiotic resistant bacterial pathogens causing secondary infections in severe cases of COVID-19.